ATHE
Alterity Therapeutics Limited
Price Chart
Latest Quote
$4.91
-0.04 (-0.83%)
Current Price
| Previous Close | $4.95 |
| Open | $5.00 |
| Day High | $5.24 |
| Day Low | $4.91 |
| Volume | 8,609 |
Stock Information
Note: Financial values converted from AUD to USD
| Shares Outstanding | 18.13M |
| Total Debt | $69K |
| Cash Equivalents | $34.37M |
| Revenue | $4.64M |
| Net Income | $-10.19M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $90.27M |
| EPS (TTM) | $-0.63 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-47.30M |
| Sales | $4.64M |
| Income | $-10.19M |
| Book/sh | $103.35 |
| Cash/sh | $2.71 |
| Employees | 9 |
Financial Ratios
| Quick Ratio | 21.68 |
| Current Ratio | 21.98 |
| Debt/Eq | 0.18 |
Returns & Margins
| ROA | -32.54% |
| ROE | -47.02% |
| Gross Margin | 97.55% |
| Operating Margin | -372.59% |
| Profit Margin | -219.85% |
Ownership
| Institutional Ownership | 1.78% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.10 |
| P/S | 13.60 |
| P/B | 0.05 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $12.67 |
Technical Indicators
| SMA20 | $5.19 |
| SMA50 | $4.66 |
| SMA200 | $3.94 |
| RSI | 53.01 |
| ATR | 0.3507 |
| Shares Float | 288K |
| Short Float | 0.22% |
| Short Ratio | 0.38 |
| Volatility | -0.03 |
| Rel Volume | 0.41 |
Performance History
| Week | -8.29% |
| Month | +7.10% |
| Quarter | +25.44% |
| 6 Months | +50.00% |
| YTD | +57.59% |
| Year | +7.33% |
| 3 Years | +76.60% |
| 5 Years | -70.36% |
| 10 Years | -89.24% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $4.98 | 9,400 |
| 2026-07-16 | $5.09 | 12,600 |
| 2026-07-15 | $4.99 | 24,900 |
| 2026-07-14 | $5.03 | 22,500 |
| 2026-07-13 | $5.38 | 5,200 |
| 2026-07-10 | $5.43 | 5,800 |
| 2026-07-09 | $5.38 | 25,500 |
| 2026-07-08 | $5.58 | 6,500 |
| 2026-07-07 | $5.49 | 18,900 |
| 2026-07-06 | $5.89 | 17,900 |
| 2026-07-02 | $5.36 | 20,000 |
| 2026-07-01 | $5.46 | 34,500 |
| 2026-06-30 | $5.37 | 90,000 |
| 2026-06-29 | $4.89 | 21,700 |
| 2026-06-26 | $4.82 | 23,400 |
| 2026-06-25 | $4.90 | 41,800 |
| 2026-06-24 | $5.07 | 34,500 |
| 2026-06-23 | $4.96 | 13,700 |
| 2026-06-22 | $4.93 | 7,200 |
| 2026-06-18 | $4.88 | 19,300 |
About Alterity Therapeutics Limited
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
đ° Latest News
Is Allarity Therapeutics, Inc. (ALLR) Outperforming Other Medical Stocks This Year?
Zacks âĸ 2026-06-19T13:40:02Z
Alterity Therapeutics Limited's (ASX:ATH) Path To Profitability
Simply Wall St. âĸ 2025-10-11T22:34:33Z
Alterity Says Data Showed Potential Multiple System Atrophy Drug Slowed Disease Progression in Phase 2 Study
MT Newswires âĸ 2025-10-09T12:19:40ZAlterity Therapeutics (ATHE) Presents Positive Phase 2 Data for ATH434
Insider Monkey âĸ 2025-09-30T19:01:34Z
We Think Alterity Therapeutics (ASX:ATH) Can Easily Afford To Drive Business Growth
Simply Wall St. âĸ 2025-08-31T23:26:25Z
Alterity Therapeutics Limited (ATHE) Announces Positive Topline Data From Phase 2 Trial of ATH434 in Multiple System Atrophy
Insider Monkey âĸ 2025-08-17T05:56:50Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $8,628,574 | $13,573,750 | $10,051,928 | $10,589,984 |
| Other Income Expense | $-134,589 | $39,542 | $454,549 | $1,649,479 |
| Other Non Operating Income Expenses | $-87,638 | $-143,158 | $-199,431 | $-255,118 |
| Net Non Operating Interest Income Expense | $312,223 | $187,784 | $11,499 | $1,752 |
| Operating Expense | $8,628,574 | $13,573,750 | $10,051,928 | $10,589,984 |
| Other Operating Expenses | $-1,479,875 | $3,664 | $19,100 | $-316,891 |
| General And Administrative Expense | $3,738,588 | $3,235,475 | $3,466,005 | $3,819,575 |
| Rent Expense Supplemental | - | - | $48,016 | $55,498 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-8,498,551 | $-13,378,666 | $-9,658,959 | $-8,987,730 |
| Net Interest Income | $312,223 | $187,784 | $11,499 | $1,752 |
| Interest Income | $312,223 | $187,784 | $11,499 | $1,752 |
| Normalized Income | $-8,465,685 | $-13,506,556 | $-10,116,745 | $-10,320,948 |
| Net Income From Continuing And Discontinued Operation | $-8,498,551 | $-13,378,666 | $-9,658,959 | $-8,987,730 |
| Net Income Common Stockholders | $-8,498,551 | $-13,378,666 | $-9,658,959 | $-8,987,730 |
| Net Income | $-8,498,551 | $-13,378,666 | $-9,658,959 | $-8,987,730 |
| Net Income Including Noncontrolling Interests | $-8,498,551 | $-13,378,666 | $-9,658,959 | $-8,987,730 |
| Net Income Continuous Operations | $-8,498,551 | $-13,378,666 | $-9,658,959 | $-8,987,730 |
| Pretax Income | $-8,450,940 | $-13,346,423 | $-9,585,880 | $-8,938,753 |
| Interest Income Non Operating | $312,223 | $187,784 | $11,499 | $1,752 |
| Operating Income | $-8,628,574 | $-13,573,750 | $-10,051,928 | $-10,589,984 |
| Depreciation Amortization Depletion Income Statement | $97,744 | $103,210 | $71,543 | $37,928 |
| Depreciation And Amortization In Income Statement | $97,744 | $103,210 | $71,543 | $37,928 |
| Depreciation Income Statement | $97,744 | $103,210 | $71,543 | $37,928 |
| Per Share | ||||
| Diluted EPS | $-0.80 | $-2.18 | $-2.39 | $-2.22 |
| Basic EPS | $-0.80 | $-2.18 | $-2.39 | $-2.22 |
| Other | ||||
| Tax Effect Of Unusual Items | $-14,085 | $54,810 | $196,194 | $571,379 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-8,483,880 | $-13,653,240 | $-10,634,366 | $-12,456,652 |
| Total Unusual Items | $-46,950 | $182,700 | $653,981 | $1,904,596 |
| Total Unusual Items Excluding Goodwill | $-46,950 | $182,700 | $653,981 | $1,904,596 |
| Reconciled Depreciation | $97,744 | $103,210 | $71,543 | $37,928 |
| EBITDA (Bullshit earnings) | $-8,530,830 | $-13,470,539 | $-9,980,385 | $-10,552,056 |
| EBIT | $-8,628,574 | $-13,573,750 | $-10,051,928 | $-10,589,984 |
| Diluted Average Shares | $7,458,752 | $4,254,554 | $2,830,840 | $2,805,361 |
| Basic Average Shares | $7,458,752 | $4,254,554 | $2,830,840 | $2,805,361 |
| Diluted NI Availto Com Stockholders | $-8,498,551 | $-13,378,666 | $-9,658,959 | $-8,987,730 |
| Tax Provision | $47,611 | $32,243 | $73,079 | $48,977 |
| Gain On Sale Of Security | $-46,950 | $182,700 | $653,981 | $1,904,596 |
| Other Taxes | $-3,805,036 | $-2,811,869 | $-2,738,373 | $-3,266,689 |
| Research And Development | $10,077,153 | $13,043,268 | $9,233,653 | $10,316,060 |
| Selling General And Administration | $3,738,588 | $3,235,475 | $3,466,005 | $3,819,575 |
| Other Gand A | $1,936,532 | $1,784,536 | $1,588,818 | $1,757,884 |
| Insurance And Claims | $384,363 | $473,079 | $504,920 | $458,927 |
| Salaries And Wages | $1,417,693 | $977,860 | $1,324,251 | $1,547,267 |
| Rent And Landing Fees | - | - | $48,016 | $55,498 |
Fetched: 2026-07-16
Balance Sheet (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $29,664,956 | $9,653,041 | $15,959,780 | $24,813,623 |
| Total Assets | $32,199,777 | $13,448,820 | $19,111,261 | $28,937,045 |
| Total Non Current Assets | $108,559 | $130,742 | $188,095 | $152,877 |
| Current Assets | $32,091,218 | $13,318,078 | $18,923,166 | $28,784,168 |
| Other Current Assets | $29,254 | $28,451 | $27,819 | $7,158 |
| Prepaid Assets | $862,685 | $1,620,003 | $1,797,623 | $1,120,538 |
| Receivables | $2,754,727 | $2,827,533 | $6,062,477 | $3,305,835 |
| Taxes Receivable | $2,754,727 | $2,827,423 | $6,016,384 | $3,305,823 |
| Accrued Interest Receivable | $0 | $110 | $459 | $13 |
| Cash Cash Equivalents And Short Term Investments | $28,444,553 | $8,842,091 | $11,035,248 | $24,350,637 |
| Cash And Cash Equivalents | $23,197,596 | $8,842,091 | $11,035,248 | $24,350,637 |
| Accounts Receivable | - | $0 | $45,634 | $0 |
| Debt | ||||
| Total Debt | $108,757 | $111,267 | $147,183 | $82,195 |
| Long Term Debt And Capital Lease Obligation | $61,946 | $36,319 | $72,203 | $41,876 |
| Current Debt And Capital Lease Obligation | $46,811 | $74,948 | $74,980 | $40,319 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $2,534,822 | $3,795,779 | $3,151,481 | $4,123,423 |
| Total Non Current Liabilities Net Minority Interest | $61,946 | $36,319 | $85,847 | $51,497 |
| Current Liabilities | $2,472,876 | $3,759,460 | $3,065,634 | $4,071,925 |
| Other Current Liabilities | $97 | $69,959 | - | $-18,836 |
| Payables And Accrued Expenses | $1,813,187 | $3,243,278 | $2,480,508 | $3,572,486 |
| Payables | $401,433 | $427,846 | $1,243,864 | $3,572,486 |
| Other Payable | $13,469 | $10,096 | $23,726 | $40,312 |
| Total Tax Payable | $11,389 | $11,190 | $19,540 | $18,836 |
| Accounts Payable | $376,575 | $406,560 | $1,200,598 | $3,553,650 |
| Equity | ||||
| Common Stock Equity | $29,664,956 | $9,653,041 | $15,959,780 | $24,813,623 |
| Total Equity Gross Minority Interest | $29,664,956 | $9,653,041 | $15,959,780 | $24,813,623 |
| Stockholders Equity | $29,664,956 | $9,653,041 | $15,959,780 | $24,813,623 |
| Other Equity Interest | $3,737,445 | $3,362,392 | $2,779,121 | $2,494,696 |
| Retained Earnings | $-158,030,424 | $-149,825,898 | $-136,512,450 | $-127,245,274 |
| Gains Losses Not Affecting Retained Earnings | - | - | - | $2,494,696 |
| Other | ||||
| Ordinary Shares Number | $127,709,122 | $73,389,051 | $34,138,767 | $33,676,712 |
| Share Issued | $127,709,122 | $73,389,051 | $34,138,767 | $33,676,712 |
| Tangible Book Value | $29,664,956 | $9,653,041 | $15,959,780 | $24,813,623 |
| Invested Capital | $29,664,956 | $9,653,041 | $15,959,780 | $24,813,623 |
| Working Capital | $29,618,342 | $9,558,618 | $15,857,532 | $24,712,243 |
| Capital Lease Obligations | $108,757 | $111,267 | $147,183 | $82,195 |
| Total Capitalization | $29,664,956 | $9,653,041 | $15,959,780 | $24,813,623 |
| Capital Stock | $183,957,934 | $156,116,547 | $149,693,109 | $149,564,201 |
| Common Stock | $183,957,934 | $156,116,547 | $149,693,109 | $149,564,201 |
| Long Term Capital Lease Obligation | $61,946 | $36,319 | $72,203 | $41,876 |
| Current Capital Lease Obligation | $46,811 | $74,948 | $74,980 | $40,319 |
| Pensionand Other Post Retirement Benefit Plans Current | $612,780 | $371,274 | $510,146 | $459,121 |
| Current Accrued Expenses | $1,411,754 | $2,815,432 | $1,236,644 | $1,650,896 |
| Net PPE | $108,559 | $130,742 | $188,095 | $152,877 |
| Gross PPE | $108,559 | $130,742 | $509,857 | $512,843 |
| Other Properties | $108,559 | $130,742 | $509,857 | $512,843 |
| Other Short Term Investments | $5,246,957 | - | - | - |
| Employee Benefits | - | $0 | $13,644 | $9,622 |
| Non Current Pension And Other Postretirement Benefit Plans | - | $0 | $13,644 | - |
| Accumulated Depreciation | - | $-302,364 | $-321,762 | $-359,966 |
Fetched: 2026-07-16
Cash Flow Statement (Annual)
| Metric | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-8,011,227 | $-8,822,965 | $-14,022,071 | $-8,693,453 |
| Operating Activities | ||||
| Operating Cash Flow | $-8,011,227 | $-8,818,962 | $-14,016,957 | $-8,631,086 |
| Cash Flow From Continuing Operating Activities | $-8,011,227 | $-8,818,962 | $-14,016,957 | $-8,631,086 |
| Operating Gains Losses | $-181,498 | $-182,700 | $-641,983 | $-1,968,403 |
| Cash Flowsfromusedin Operating Activities Direct | $-8,011,227 | $-8,818,962 | $-14,016,957 | $-8,631,086 |
| Classesof Cash Receiptsfrom Operating Activities | $3,938,420 | $6,004,951 | - | $3,204,480 |
| Other Cash Receiptsfrom Operating Activities | - | - | - | $317,700 |
| Investing Activities | ||||
| Investing Cash Flow | $-5,246,957 | $-4,003 | $-25,508 | $-62,367 |
| Cash Flow From Continuing Investing Activities | $-5,246,957 | $-4,003 | $-25,508 | $-62,367 |
| Capital Expenditure | - | $-4,003 | $-5,115 | $-62,367 |
| Net Other Investing Changes | - | - | $-20,393 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $29,782,179 | $7,097,161 | $221,544 | $12,016,259 |
| Financing Cash Flow | $27,752,471 | $6,447,665 | $86,988 | $11,406,575 |
| Cash Flow From Continuing Financing Activities | $27,752,471 | $6,447,665 | $86,988 | $11,406,575 |
| Net Other Financing Charges | $-1,940,792 | $-642,242 | $-92,635 | $-585,539 |
| Net Common Stock Issuance | $29,782,179 | $7,097,161 | $221,544 | $12,016,259 |
| Common Stock Issuance | $29,782,179 | $7,097,161 | $221,544 | $12,016,259 |
| Other | ||||
| Repayment Of Debt | $-88,916 | $-7,255 | $-41,921 | $-24,145 |
| End Cash Position | $23,197,596 | $8,842,091 | $11,035,248 | $24,350,637 |
| Beginning Cash Position | $8,842,091 | $11,035,248 | $24,350,637 | $19,669,454 |
| Effect Of Exchange Rate Changes | $-138,782 | $182,144 | $640,088 | $1,968,061 |
| Changes In Cash | $14,494,286 | $-2,375,300 | $-13,955,477 | $2,713,122 |
| Net Issuance Payments Of Debt | $-88,916 | $-7,255 | $-41,921 | $-24,145 |
| Net Long Term Debt Issuance | $-88,916 | $-7,255 | $-41,921 | $-24,145 |
| Long Term Debt Payments | $-88,916 | $-7,255 | $-41,921 | $-24,145 |
| Net Investment Purchase And Sale | $-5,246,957 | $0 | $0 | - |
| Purchase Of Investment | $-5,246,957 | $0 | $0 | - |
| Net PPE Purchase And Sale | $0 | $-4,003 | $-5,115 | $-62,367 |
| Purchase Of PPE | $0 | $-4,003 | $-5,115 | $-62,367 |
| Change In Working Capital | $-429,326 | $4,022,186 | $-4,470,924 | $1,233,402 |
| Change In Other Working Capital | $241,506 | $-152,516 | $55,048 | $85,969 |
| Change In Other Current Liabilities | $-69,862 | $-8,350 | $0 | $0 |
| Change In Other Current Assets | $756,515 | $176,988 | $-677,352 | $-361,114 |
| Change In Payables And Accrued Expense | $-1,430,290 | $771,120 | $-1,091,978 | $1,821,744 |
| Change In Payable | $-1,430,290 | $771,120 | $-1,091,978 | $1,821,744 |
| Change In Receivables | $72,805 | $3,234,944 | $-2,756,641 | $-313,197 |
| Other Non Cash Items | $314,857 | - | - | $43 |
| Stock Based Compensation | $685,546 | $617,007 | $676,208 | $1,053,674 |
| Asset Impairment Charge | $0 | $0 | $7,158 | $0 |
| Depreciation Amortization Depletion | $97,744 | $103,210 | $71,543 | $37,928 |
| Depreciation And Amortization | $97,744 | $103,210 | $71,543 | $37,928 |
| Depreciation | $97,744 | $103,210 | $71,543 | $37,928 |
| Net Foreign Currency Exchange Gain Loss | $-181,498 | $-182,700 | $-641,983 | $-1,968,403 |
| Net Income From Continuing Operations | $-8,498,551 | $-13,378,666 | $-9,658,959 | $-8,987,730 |
| Taxes Refund Paid Direct | $3,890,809 | $5,964,359 | $-72,375 | $2,856,639 |
| Interest Received Direct | $312,223 | $188,243 | $11,052 | $1,927 |
| Interest Paid Direct | $0 | $-5,049 | $-3,194 | $-1,599 |
| Classesof Cash Payments | $-12,261,870 | $-15,007,108 | $-14,024,815 | $-11,835,895 |
| Paymentsto Suppliersfor Goodsand Services | $-12,214,259 | $-14,966,515 | $-13,952,440 | $-11,805,754 |
| Receiptsfrom Government Grants | - | - | $0 | $317,700 |
Fetched: 2026-07-16